Networking to Reduce Risk
Pharmaceutical and biotech organisations carry the responsibility for their patients’ safety. In these businesses, drug safety is a life-critical process where these organisations are responsible for reporting and managing all adverse drug reactions and associated risks. It’s a highly regulated aspect of the business, with the EMEA and FDA watching over in Europe and the USA.
It’s also one that is constantly changing. Not only has there been an increase in the number of adverse events and the complexity of new drugs, but new legislation is often introduced, and existing regulations are continually updated. Compliance is rigorously monitored, and organisations are subject to reporting rules and audits. The price to pay for non-compliance is high – warning letters that risk the global reputation of the drug safety teams, and product withdrawal, which can cost the company millions of dollars and many staff jobs.
If you would like to read the article in full please click on the pdf. link below
Networking to reduce risk
If you would like further information please email info@wcigroup.com
About DIA Today
Established in 2001 DIA Today is a publication of the Drug Information Association aimed to better communicate the activities and programs of the DIA to its members. It is distributed to members as a benefit of membership with a circulation figure of 23,000.
For further information please visit the DIA website at www.diahome.org